Sign In
Buy PHAT
$10.09
+0.440 (+4.56%)
At Close: Jun 03, 2026
Phathom's stock falls after receiving FDA letters
07:59am, Friday, 10'th Feb 2023
Shares of Phathom Pharmaceuticals Inc. PHAT, -0.60% tumbled about 23% in premarket trading on Friday, the day after the company said it received complete response letters from the Food and Drug Admini
Why Shares of Phathom Pharmaceutical Jumped This Week
01:58pm, Saturday, 28'th Jan 2023
Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy.
Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA
12:02pm, Thursday, 05'th Jan 2023
Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.
Phathom Pharma: Approved Drugs, Upcoming PDUFA, Smallish Addressable Market
12:38pm, Thursday, 10'th Nov 2022
PHAT, a Takeda spinoff, has a drug approved in H. pylori. The same drug has a PDUFA in a GERD subtype.
Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:15am, Wednesday, 07'th Sep 2022
FLORHAM PARK, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
08:15am, Wednesday, 01'st Jun 2022
FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
08:01am, Tuesday, 17'th May 2022
FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), an innovative biopharmaceutical company focused on developing and commercializing novel treatments fo
Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
08:01am, Friday, 01'st Apr 2022
FLORHAM PARK, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel tre
Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
12:02pm, Tuesday, 22'nd Mar 2022 GlobeNewswire Inc.
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel t
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
12:02pm, Monday, 14'th Mar 2022 GlobeNewswire Inc.
FLORHAM PARK, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel t
Phathom Pharmaceuticals GAAP EPS of -$0.95 beats by $0.05 (NASDAQ:PHAT)
10:04pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Phathom Pharmaceuticals press release (PHAT): Q4 GAAP EPS of -$0.95 beats by $0.05.As of December 31, 2021, cash and cash equivalents were $183.3 million
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
09:04pm, Tuesday, 01'st Mar 2022 GlobeNewswire
FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided highlights of pipeline and business progress.
Phathom Pharma''s Digestive Disease Candidate Meets Primary Goal In Mid-Stage Study
03:02pm, Thursday, 10'th Feb 2022 Benzinga
Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episodic heartburn in non-erosive gastroesophageal reflux disease (NERD). All three vonoprazan dose levels met the primary endpoint and were statistically significant compared to placebo in the study. Within three hours, vonoprazan … Full story available on Benzinga.com
Phathom Pharma's Digestive Disease Candidate Meets Primary Goal In Mid-Stage Study
10:02am, Thursday, 10'th Feb 2022
Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episodic heartburn in non-erosive gastroesophageal reflu
Phathom says mid-stage study for vonoprazan in gastroesophageal reflux met main goal
10:02pm, Wednesday, 09'th Feb 2022 Seeking Alpha
Announcing topline data from its PHALCON-NERD trial for vonoprazan, Phathom Pharmaceuticals (PHAT) said that the experimental on-demand therapy for episodic heartburn met the main goal…
